The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2010HE3286 as Treatment for Parkinson's Disease
Objective/Rationale:
Dehydroepiandrosterone (DHEA), a common neutraceutical and potent neuro-steroid has been suggested as a neuroprotective treatment for Parkinson’s disease (PD). However, DHEA is... -
Therapeutics Development Initiative, 2010Evaluation of the Neuroprotectivity Ability of Zymes' Water-soluble CoQ10 (WS-CoQ10) in Pre-clinical Models of PD; Preclinical Validation and Dose Optimization for Clinical Study
Objective/Rationale:
Coenzyme Q10 is a lipid soluble naturally occurring compound essential for energy production and defence against oxidative stress. Recent clinical studies indicate that it may... -
Therapeutics Development Initiative, 2010A Novel Prodrug of Acamprosate for Treatment of L-DOPA-Induced Dyskinesias
Objective/Rationale:
The primary objective of this proposal is to determine if a prodrug of acamprosate could inhibit L-DOPA induced dyskinesias (LID). Functional interactions between the dopamine... -
Alpha-Synuclein Therapeutics, 2010Targeting Alpha-Synuclein Dephosphorylation via PP2A Activation as a Novel PD Therapeutic
Objective/Rationale:
Alpha-synuclein is a prime target for Parkinson’s disease (PD). Excessive phosphorylation of alpha-synuclein can contribute to pathology, thus mechanisms to decrease its... -
Alpha-Synuclein Therapeutics, 2010Use of the Orally Administered Pharmacological Chaperone AT3375 to Reduce Alpha-synuclein Levels in the Brain of Thy-1 Alpha-synuclein Small Models
Objective/Rationale:
Mutations in the GBA1 gene increase the risk of Parkinson’s. These mutations reduce the activity of the enzyme glucocerebrosidase (GCase), which is deficient in the lysosomal... -
Alpha-Synuclein Therapeutics, 2010AFFITOPE based immunotherapeutic strategies for Parkinson´s disease
Objective/Rationale:
Parkinson’s disease (PD) is characterized by the formation of abnormal alpha-synuclein accumulations, so called Lewy bodies, in the nervous system. Alpha-synuclein is currently...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.